Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.74
Dollar change
-0.02
Percentage change
-0.72
%
Index- P/E- EPS (ttm)-1.48 Insider Own33.41% Shs Outstand26.57M Perf Week0.37%
Market Cap75.54M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float18.36M Perf Month-0.36%
Income-39.24M PEG- EPS next Q- Inst Own61.12% Short Float0.07% Perf Quarter4.58%
Sales0.00M P/S- EPS this Y- Inst Trans-1.64% Short Ratio1.80 Perf Half Y5.79%
Book/sh4.00 P/B0.69 EPS next Y- ROA-30.95% Short Interest0.01M Perf Year-16.46%
Cash/sh3.90 P/C0.70 EPS next 5Y- ROE-32.15% 52W Range2.34 - 3.72 Perf YTD1.48%
Dividend Est.- P/FCF- EPS past 5Y- ROI-35.74% 52W High-26.34% Beta0.51
Dividend TTM- Quick Ratio38.76 Sales past 5Y0.00% Gross Margin- 52W Low17.09% ATR (14)0.14
Dividend Ex-Date- Current Ratio38.76 EPS Y/Y TTM18.93% Oper. Margin0.00% RSI (14)50.05 Volatility5.29% 4.89%
Employees43 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price24.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q60.12% Payout- Rel Volume0.38 Prev Close2.76
Sales Surprise- EPS Surprise-236.00% Sales Q/Q- Earnings- Avg Volume7.21K Price2.74
SMA20-0.41% SMA500.01% SMA2001.19% Trades Volume2,767 Change-0.72%
Jul-21-23 07:17AM
Jul-20-23 06:45AM
May-11-23 04:10PM
Apr-21-23 12:00PM
10:39AM
04:10PM Loading…
Mar-06-23 04:10PM
Feb-23-23 12:38AM
Feb-10-23 09:31AM
Feb-09-23 04:01PM
Nov-30-22 07:00AM
Nov-14-22 06:10AM
Nov-12-22 08:47AM
Nov-08-22 07:00AM
Oct-05-22 11:20AM
07:00AM
06:10AM Loading…
Aug-15-22 06:10AM
Aug-02-22 09:33AM
07:58AM
07:00AM
Jul-18-22 09:20AM
07:00AM
Jul-07-22 07:00AM
Jun-27-22 04:01PM
May-16-22 06:10AM
May-10-22 10:45AM
May-09-22 09:55AM
Apr-25-22 07:00AM
Apr-05-22 07:00AM
Mar-21-22 07:00AM
Mar-07-22 04:10PM
07:00AM Loading…
Feb-11-22 07:00AM
Feb-07-22 07:00AM
Jan-18-22 07:00AM
Nov-25-21 07:35AM
Nov-08-21 04:01PM
Nov-04-21 07:00AM
Oct-04-21 10:54AM
Sep-13-21 04:10PM
Aug-16-21 10:22AM
Aug-12-21 09:06PM
Aug-09-21 10:33PM
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morisset ValerieEVP, R&D AND CSOSep 20 '23Option Exercise0.0020,72814487,460Mar 04 11:07 AM